George Grigonis, Jr. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
George Grigonis, Jr.


George Grigonis, Jr.
Consultant

George J. Grigonis, Jr. is a systems quality assurance and systems validation professional with 21 years of experience in pharmaceutical industry process validation and computer validation methods for both regulated and non-regulated environments. Formerly, Grigonis was affiliated with Merck & Co., Inc. as manager and consultant in information services. He was principally responsible for quality assurance and validation practices for the company’s computing environments and managed the corporate and divisional programs for supplier evaluation and management in the procurement of automation products and services. He has held senior consultant positions in several consulting firms providing services for computer validation and electronic records management.  

Grigonis has served on various industry committees and task groups for computer validation, compliance and electronic records. He was the lead architect for the PDA’s Supplier Auditing and Qualification Task Group that resulted in the TR-32 Program and was the principal investigator that resulted in PDA’s Task Group on Part 11 and the GERM guidance for electronic records management.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
14%
Less restrictive inventory control by pharmaceutical companies
9%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here